That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

which was acquired by GSK when it took over Tesaro in a $5.1 billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib). There are a number of other TIM-3 targeting drugs coming ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Depemokimab is an inhibitor of IL-5 ... for treating eosinophilic granulomatosis with polyangiitis. GSK has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab ... with an average gain of +24.3% per year. So be sure to give ...